Health News (Reuters)

Zika vaccine shows promise in early human trial

CHICAGO (Reuters) - A DNA-based Zika vaccine from Inovio Pharmaceuticals Inc and South Korea's GeneOne Life Science Inc induced anti-Zika immune responses in an early stage human trial, U.S. researchers reported on Wednesday.

Insurers are slow to approve pricey new cholesterol drugs

(Reuters Health) - During the first year an expensive class of new cholesterol-lowering drugs was on the market, only one in three patients with a prescription actually received the therapy due to lack of insurance approval and high copays, according to a study sponsored by a manufacturer of one such drug.

Mylan surges, Teva slumps after FDA approves Copaxone copy

(Reuters) - Mylan NV's long-awaited U.S. approval for its generic version of rival Teva's blockbuster multiple sclerosis treatment Copaxone drove Mylan's shares up around 18 percent on Wednesday while Teva shares plunged.

Drug industry fails to win judicial review of new UK cost curbs

LONDON (Reuters) - Britain's pharmaceuticals industry failed to secure a judicial review of new cost curbs, which mean drugs costing NHS England more than 20 million pounds ($26 million) annually no longer get automatic funding.

Mylan surges, Teva slumps after FDA okays Copaxone copy

(Reuters) - Mylan NV's long-awaited U.S. approval for its generic version of rival Teva's blockbuster multiple sclerosis treatment (MS) Copaxone drove the drugmaker's shares up more than 19 percent on Wednesday morning and hurt Teva shares.

Obamacare sign-up challenge: proving the law is not dead

NOGALES, Arizona (Reuters) - More than two thousand miles away from the healthcare debate in Washington, President Donald Trump's threats to let Obamacare collapse are sowing confusion about its fate and dampening 2018 enrollment expectations.

Mylan surges as its generic of Teva's Copaxone gets FDA nod

(Reuters) - Shares of Mylan NV jumped about 17 percent in premarket trading on Wednesday after the U.S. Food and Drug Administration approved the drugmaker's copycat version of Teva Pharmaceutical Industries Ltd's blockbuster multiple sclerosis drug.

Sap from garden plants can burn eyes

(Reuters Health) - Gardeners caring for plants in the Euphorbia genus should be careful about handling the toxic sap, according to a new report.

ACLU sues over FDA restrictions on abortion pill access

(Reuters) - The American Civil Liberties Union filed a lawsuit on Tuesday seeking to challenge U.S. Food and Drug Administration restrictions that limit the ability of women to access the so-called abortion pill.

Plastic surgery videos need strict ethics standards, doctors argue

(Reuters Health) - Some plastic surgeons have gained large social media followings by sharing theatrical videos of surgery with entertainment, rather than education, in mind. Now experts are proposing ethics guidelines to ensure that the content of plastic surgery videos on social media isn’t harmful to patients.

Meditation may help prevent heart disease, doctors say

(Reuters Health) - Meditation may help reduce the risk of heart disease when it’s added to proven approaches like lifestyle changes or drugs to lower blood pressure and cholesterol, U.S. doctors say.

Allergan CEO says patent review flawed in response to senators

NEW YORK (Reuters) - Allergan Plc Chief Executive Brent Saunders on Tuesday defended his company's decision to transfer drug patents to a Native American tribe as a proper way to shield them from a flawed patent review process, in a response to congressional criticism.